Vanda Pharmaceuticals Inc. – NASDAQ:VNDA
Founder-led company
Vanda Pharmaceuticals stock price today
$4.56
-0.25
-5.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Vanda Pharmaceuticals stock price monthly change
-18.75%
month
Vanda Pharmaceuticals stock price quarterly change
-18.75%
quarter
Vanda Pharmaceuticals stock price yearly change
+11.86%
year
Vanda Pharmaceuticals key metrics
Market Cap | 272.59M |
Enterprise value | 257.72M |
P/E | 61.82 |
EV/Sales | 1.01 |
EV/EBITDA | 26.97 |
Price/Sales | 1.50 |
Price/Book | 0.72 |
PEG ratio | -0.75 |
EPS | -0.08 |
Revenue | 177.60M |
EBITDA | -21.05M |
Income | -4.88M |
Revenue Q/Q | -24.05% |
Revenue Y/Y | -30.80% |
Profit margin | 2.47% |
Oper. margin | 2.49% |
Gross margin | 90.45% |
EBIT margin | 2.49% |
EBITDA margin | -11.85% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVanda Pharmaceuticals stock price history
Vanda Pharmaceuticals stock forecast
Vanda Pharmaceuticals financial statements
| Jun 2023 | 46.05M | 1.52M | 3.3% |
|---|---|---|---|
| Sep 2023 | 38.81M | 137K | 0.35% |
| Dec 2023 | 45.27M | -2.4M | -5.3% |
| Mar 2024 | 47.46M | -4.14M | -8.74% |
| 2025 | 175.3M | -28.1M | -16.03% |
|---|---|---|---|
| 2026 | 152.1M | 7.48M | 4.92% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 641682000 | 101.78M | 15.86% |
|---|---|---|---|
| Sep 2023 | 641605000 | 98.50M | 15.35% |
| Dec 2023 | 648440000 | 103.53M | 15.97% |
| Mar 2024 | 652682000 | 108.68M | 16.65% |
| Jun 2023 | -13.22M | -190.89M | 0 |
|---|---|---|---|
| Sep 2023 | -2.05M | 35.32M | 0 |
| Dec 2023 | -3.73M | -43.78M | 0 |
| Mar 2024 | 7.56M | -18.21M | 0 |
Vanda Pharmaceuticals alternative data
| Aug 2023 | 290 |
|---|---|
| Sep 2023 | 290 |
| Oct 2023 | 290 |
| Nov 2023 | 290 |
| Dec 2023 | 290 |
| Jan 2024 | 290 |
| Feb 2024 | 290 |
| Mar 2024 | 203 |
| Apr 2024 | 203 |
| May 2024 | 203 |
| Jun 2024 | 203 |
| Jul 2024 | 203 |
Vanda Pharmaceuticals other data
84.61%
-15.21%
of VNDA is owned by hedge funds
157
-8
48.07M
-7.92M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 30600 |
| Jul 2023 | 0 | 2212 |
| Aug 2023 | 0 | 10224 |
| Mar 2024 | 0 | 121098 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | WILLIAMS TIMOTHY officer: SVP & General Counsel | Common Stock | 8,941 | $4.18 | $37,400 | ||
Sale | WIJKSTROM JOAKIM officer: SVP, Chi.. | Common Stock | 9,229 | $4.21 | $38,826 | ||
Sale | POLYMEROPOULOS MIHAEL HRISTOS director, officer.. | Common Stock | 24,288 | $4.13 | $100,285 | ||
Sale | MORAN KEVIN PATRICK officer: SVP, CFO.. | Common Stock | 8,902 | $4.2 | $37,415 | ||
Sale | MORAN KEVIN PATRICK officer: SVP, CFO.. | Common Stock | 8,902 | $4.2 | $37,415 | ||
Sale | BIRZNIEKS GUNTHER officer: SVP, Business Developm.. | Common Stock | 8,684 | $4.13 | $35,882 | ||
Sale | WILLIAMS TIMOTHY officer: SVP & General Counsel | Common Stock | 8,147 | $4.41 | $35,920 | ||
Sale | WIJKSTROM JOAKIM officer: SVP, Chi.. | Common Stock | 7,498 | $4.41 | $33,089 | ||
Sale | POLYMEROPOULOS MIHAEL HRISTOS director, officer.. | Common Stock | 30,884 | $4.24 | $131,072 | ||
Sale | MORAN KEVIN PATRICK officer: SVP, CFO.. | Common Stock | 5,798 | $4.48 | $25,981 |
| Patent |
|---|
Application Filling date: 26 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 8 Apr 2022 Issue date: 18 Aug 2022 |
Application Filling date: 28 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 6 Apr 2022 Issue date: 21 Jul 2022 |
Application Filling date: 15 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 15 Feb 2022 Issue date: 2 Jun 2022 |
Application Filling date: 15 Feb 2022 Issue date: 2 Jun 2022 |
Grant Utility: Method of treatment with tradipitant Filling date: 31 Jul 2020 Issue date: 10 May 2022 |
Application Filling date: 14 Jan 2022 Issue date: 5 May 2022 |
Application Filling date: 3 Dec 2019 Issue date: 31 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Vanda Pharmaceuticals: FDA Approvals On Deck In 2024 Makes This A Must Watch
The Right Play On Intra-Cellular Therapies
Vanda Pharmaceuticals: Value In The Biotech Space
Vanda: VPO-227 Advancement Signals More Upsides
Vanda Pharmaceuticals: What The Recent Partnership Entails
-
What's the price of Vanda Pharmaceuticals stock today?
One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $4.56.
-
When is Vanda Pharmaceuticals's next earnings date?
Unfortunately, Vanda Pharmaceuticals's (VNDA) next earnings date is currently unknown.
-
Does Vanda Pharmaceuticals pay dividends?
No, Vanda Pharmaceuticals does not pay dividends.
-
How much money does Vanda Pharmaceuticals make?
Vanda Pharmaceuticals has a market capitalization of 272.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 24.27% to 192.64M US dollars.
-
What is Vanda Pharmaceuticals's stock symbol?
Vanda Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "VNDA".
-
What is Vanda Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vanda Pharmaceuticals?
Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vanda Pharmaceuticals's key executives?
Vanda Pharmaceuticals's management team includes the following people:
- Dr. Mihael H. Polymeropoulos Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,440,000)
- Mr. Joakim Wijkstrom Senior Vice President & Chief Marketing Officer(age: 59, pay: $786,370)
- Mr. Kevin Patrick Moran Senior Vice President, Chief Financial Officer & Treasurer(age: 41, pay: $755,630)
- Mr. Timothy Williams Senior Vice President, Gen. Counsel & Sec.(age: 49, pay: $641,550)
-
Is Vanda Pharmaceuticals founder-led company?
Yes, Vanda Pharmaceuticals is a company led by its founder Dr. Mihael H. Polymeropoulos.
-
How many employees does Vanda Pharmaceuticals have?
As Jul 2024, Vanda Pharmaceuticals employs 203 workers.
-
When Vanda Pharmaceuticals went public?
Vanda Pharmaceuticals Inc. is publicly traded company for more then 19 years since IPO on 12 Apr 2006.
-
What is Vanda Pharmaceuticals's official website?
The official website for Vanda Pharmaceuticals is vandapharma.com.
-
Where are Vanda Pharmaceuticals's headquarters?
Vanda Pharmaceuticals is headquartered at 2200 Pennsylvania Avenue NW, Washington, DC.
-
How can i contact Vanda Pharmaceuticals?
Vanda Pharmaceuticals's mailing address is 2200 Pennsylvania Avenue NW, Washington, DC and company can be reached via phone at +20 2 7343400.
Vanda Pharmaceuticals company profile:
Vanda Pharmaceuticals Inc.
vandapharma.comExchange:
NASDAQ
Full time employees:
203
Industry:
Biotechnology
Sector:
Healthcare
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue NW
Washington, DC 20037
Washington, DC 20037
CIK: 0001347178
ISIN: US9216591084
CUSIP: 921659108
